✦ LIBER ✦

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

✍ Scribed by Langdahl, Bente; Binkley, Neil; Bone, Henry; Gilchrist, Nigel; Resch, Heinrich; Rodriguez Portales, Jose; Denker, Andrew; Lombardi, Antonio; Le Bailly De Tilleghem, Celine; DaSilva, Carolyn; Rosenberg, Elizabeth; Leung, Albert

Book ID: 118762378
Publisher: American Society for Bone and Mineral Research
Year: 2012
Tongue: English
Weight: 133 KB
Volume: 27
Category: Article
ISSN: 0884-0431
DOI: 10.1002/jbmr.1695

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Odanacatib in the treatment of postmenop

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

✍ John A Eisman; Henry G Bone; David J Hosking; Michael R McClung; Ian R Reid; Ren 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 211 KB 👁 2 views

## Abstract The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone‐resorption markers during 2 years of treatment in postmenopausal women with low BMD. A 1‐year extension study further assessed ODN efficacy and safety and the effec

Odanacatib in the treatment of postmenop

Odanacatib in the treatment of postmenopausal women with low bone mineral density: 3-year continued therapy and resolution of effect

✍ D. Hosking⁎; J.A. Eisman; H. Bone; M. McClung; I. Reid; R. Rizzoli; H. Resch; N. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Odanacatib in the Treatment of Postmenop

Odanacatib in the Treatment of Postmenopausal Women with Low Bone Mineral Density: 3-Year Continued Therapy and Resolution of Effect

✍ Ian Reid; John Eisman; Henry Bone; David Hosking; Michael McClung; Rene Rizzoli; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Four-year results of a phase 2 study of

Four-year results of a phase 2 study of the cathepsin K inhibitor odanacatib in postmenopausal women with low bone mineral density: Effects on bone mineral density and bone turnover markers

✍ H. Resch; N. Binkley; H. Bone; J. Eisman; D. Hosking; B. Langdahl; M. McClung; I 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Two year results in a randomized, double

Two year results in a randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in postmenopausal women with low bone mineral density

✍ J.A. Eisman; R.R. Recker; M. McClung; H. Bone; C. Roux; N. Verbruggen; C.M. Hust 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Treatment with the cathepsin K inhibitor

Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial

✍ B. Langdahl⁎; N. Binkley; H. Bone; N. Gilchrist; H. Resch; J. Rodriguez Portales 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 153 KB